EGFR Targeted Nanocarriers for Cancer Diagnosis and Therapy

Conventional cancer management is directly associated with many problems, including accurate therapeutic delivery to tumours and serious side effects of chemotherapeutics. A specific and efficient anticancer delivery to the tumour site without damaging normal tissues is the ultimate goal of all cancer treatment strategies. Nanomedicine has immense potential for cancer therapy that focuses on improving treatment efficacy, while reducing toxicity to normal tissues as well. However, the biodistribution and targeting capability of nanoparticles lacking targeting ligands rely solely on their physicochemical properties and the pathophysiological parameters of the body. Targeting is a promising strategy for selective and efficient therapeutic delivery to tumour cells with reduced detrimental side effects. Taking advantage of the fact that molecular markers and receptors over-express on the tumour cell surface as compared to a normal cell, the active targeting approach would be beneficial for cancer therapy. The epidermal growth factor receptors (EGFR), abnormally overexpressed in many epithelial tumours, have received much attention for molecular targeting in cancer diagnostics and therapeutics. This review presents the role of EGFR targeting in cancer imaging and therapy, and some recent researches on treatment of EGFR overexpressing cancers by using targeted nanoparticulate platforms. It also discusses illustrative examples of various ligands, including antibodies, antibody fragments, nanobodies, and peptides.HighlightsHighlights the potential of EGFR targeted nanocarriers for cancer diagnosis and therapy.Summarizes the role of EGFR targeting in cancer therapy.Describes various examples of recent researches on EGFR targeted nanocarriers.Explains illustrative examples of various ligands for EGFR targeting.

Nanomaterials for the diagnosis and treatment of head and neck cancers: A review

Head and neck cancer (HNC) is a category of cancers that typically arise from the nose-, mouth-, and throat-lining squamous cells. The later stage of HNC diagnosis significantly affects the patient’s survival rate. This makes it mandatory to diagnose this cancer with a suitable biomarker and imaging techniques at the earlier stages of growth. There are limitations to traditional technologies for early detection of HNC. Furthermore, the use of nanocarriers for delivering chemo-, radio-, and phototherapeutic drugs represents a promising approach for improving the outcome of HNC treatments. Several studies with nanostructures focus on the development of a targeted and sustained release of anticancer molecules with reduced side effects. Besides, nanovehicles could allow co-delivering of anticancer drugs for synergistic activity to counteract chemo-or radioresistance. Additionally, a new generation of smart nanomaterials with stimuli-responsive properties have been developed to distinguish between unique tumor conditions and healthy tissue. In this light, the present article reviews the mechanisms used by different nanostructures (metallic and metal oxide nanoparticles, polymeric nanoparticles, quantum dots, liposomes, nanomicelles, etc.) to improve cancer diagnosis and treatment, provides an up-to-date picture of the state of the art in this field, and highlights the major challenges for future improvements

Study of novel nanoparticle transport and drug release for cancer treatment.

Nano-scale particles sized 10—400 nm administered systemically preferentially extravasate from tumor vasculature due to the enhanced permeability and retention effect. Therapeutic success remains elusive, however, because of inhomogeneous particle distribution within tumor tissue. Insufficient tumor vascularization limits particle transport and also results in avascular hypoxic regions with non-proliferating cells, which can regenerate tissue after nanoparticle-delivered cytotoxicity or thermal ablation. In this study, gold nanoparticles were functionalized with phosphatidylcholine (two-layer) or phosphatidylcholine and HDL (three-layer) in the formation of “layered” nanoparticles. The diffusivity of both two- and three layered colloidal gold nanoparticles and silica gold nanoshells were examined in 3D cell cultures. Both two- and three layered nanoparticles showed enhanced diffusivity in comparison to previously developed PEGylated nanoparticles. As the two layer nanoparticles displayed enhanced diffusivity in comparison to three layer nanoparticles, the two layered nanoparticles were further examined in vivo using mice implanted with orthotopic pancreatic adenocarcinomas. The two layer colloidal gold nanoparticles showed enhanced diffusivity in comparison to silica gold nanoshells in vivo, suggesting that smaller nanoparticles were able to localize and diffuse from vasculature better than larger nanoparticles. Overall accumulation of solid gold nanoparticle accumulated in the tumor and filtering organs (liver and spleen) was 2X higher than silica gold nanoshells. Thus, two layer colloidal gold nanoparticles were loaded with cisplatin or paclitaxel to determine optimal drug release kinetics. Drug release from paclitaxel-loaded nanoparticles displayed a slower release while cisplatin-loaded nanoparticles experienced an initial burst of drug release followed by a slower release of remaining drug. Lastly, drug-loaded colloidal gold nanoparticles were tested in 3D cell cultures to determine their cytotoxicity. Both two and three layer nanoparticles loaded with cisplatin orpaclitaxel showed similar efficacy to drug alone, suggesting their viable use in vivo for cancer treatment. This study has demonstrated the potential use of layered nanoparticles for increasing the delivery of chemotherapeutics deeper into tumor tissue

Radiolabeled Compounds for Diagnosis and Treatment of Cancer

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals

Use of hybrid iron oxide-silver nanoparticles for thermo-responsive drug delivery in pancreatic cancer

Pancreatic cancer is the 4th most aggressive cancer in the Western world. There are very little drugs available as chemotherapies for the treatment of pancreatic cancer. Of the ones used, most of them become eliminated by first pass metabolism before they reach their desired site of action. Nanoparticles which can work as drug delivery systems have huge potential for the treatment of different kinds of cancer such as pancreatic cancer. The qualities of silver nanoparticles applicable to human treatments are under investigation in assessing potential efficacy, laboratory and animal studies, toxicity, and costs. Coating Iron oxide with silver nanoparticles can lead increase silver performance and it can deliver the silver nano particles and cancer drugs to the target cells. In this report, we focus on the design, synthesis, and characterization of hybrid iron oxide-silver core-shell nanostructures (HNPs). The HNP were characterised by various techniques such as magnetic properties, particle size, zeta potential, inductively coupled plasma (ICP), ultraviolet light (UV) and transmission electron microscopy (TEM). The laser mediated heating confirmed that the HNPs possessed surface plasmon resonance and hence highlights the potential of new HNP capability in thermo-responsive drug delivery. The drug conjugation, stability and releasing of HNP- BNIPDSpm and HNP-BNIPDSpm-PEG Thiol were assessed by FTIR, zeta potential and high performance liquid chromatography (HPLC). HPLC results demonstrated new formulations have high physical and formulations stabilities. PEGylated formulations demonstrated greater release of drug in comparison with their unPEGylated counterparts. The drug release were assessed and optimised in biological media and aqueous environments

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

C